Apollo Hospitals, Department of Pathology, CHENNAI, INDIA.
Turk Patoloji Derg. 2021;37(2):139-144. doi: 10.5146/tjpath.2021.01525.
Non-small cell lung carcinomas often present at an advanced stage with a grim prognosis. Immune checkpoint (ICP) inhibitors have drastically changed the scenario, and the response to ICP inhibitors is determined by analyzing the expression of PD-L1 by immunohistochemistry. PD-L1 immunohistochemistry helps in optimizing the treatment, and avoiding unnecessary exposure of patients to the toxic effects of the drugs that are ineffective and expensive in non-expressing tumors. This study was conducted to assess the prevalence of the expression of PD-L1 in non-small cell carcinomas of the lung diagnosed at our institution, which is a tertiary care center in South India.
The PD-L1 immunohistochemistry of 77 cases of non-small cell carcinomas of the lung diagnosed over a period of two years were reviewed and analyzed (2018-2020). All tissues were fixed in 10% neutral buffered formalin and processed by standard methods, and the Ventana SP263 clone was used.
Seventy-seven cases of non-small cell lung carcinomas were reviewed and studied for (PD-L1) expression. 35/77 (45%) of the cases had PD-L1 expression (≥ 1%) and 14 (18 %) had high (PD-L1) expression. Also there was a male preponderance of 2.3:1. High PD-L1 expression was seen mostly in patients above 60 years of age and was usually associated with high tumor grade.
It is important to assess PD-L1 expression in non-small cell carcinomas of patients especially with higher tumor grade and older age groups that they may benefit from immune checkpoint inhibitor therapy.
非小细胞肺癌常处于晚期，预后较差。免疫检查点（ICP）抑制剂彻底改变了这一局面，ICP 抑制剂的反应通过免疫组化分析 PD-L1 的表达来确定。PD-L1 免疫组化有助于优化治疗方案，避免将药物的毒性作用不必要地暴露于对药物无效且昂贵的非表达肿瘤的患者身上。本研究旨在评估在我们机构（印度南部的一家三级护理中心）诊断的非小细胞肺癌中 PD-L1 表达的流行率。
回顾性分析了在两年期间（2018-2020 年）诊断的 77 例非小细胞肺癌的 PD-L1 免疫组化。所有组织均用 10％中性缓冲福尔马林固定，并通过标准方法进行处理，使用 Ventana SP263 克隆。
共回顾性研究了 77 例非小细胞肺癌患者的（PD-L1）表达情况。35/77（45％）例患者 PD-L1 表达（≥1％），14（18％）例患者高（PD-L1）表达。男性也占 2.3：1 的优势。高 PD-L1 表达主要见于 60 岁以上的患者，通常与高肿瘤分级相关。
评估非小细胞肺癌患者 PD-L1 表达情况非常重要，特别是对于肿瘤分级较高和年龄较大的患者，他们可能受益于免疫检查点抑制剂治疗。
